Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (ENGOT-Cx10 / GEICO 68-C / JGOG1084 / GOG-3030 / BEATcc)

Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix

  • Cervical Cancer
Trial Status:

Active, not recruiting

This trial runs in
Cities
  • Akashi
  • Angers
  • Barcelona
  • Bergen
  • Besançon
  • Bordeaux
  • Caen
  • Candiolo
  • Cona
  • Córdoba
  • Donostia
  • El Palmar
  • Girona
  • Hidaka
  • Koto City
  • Kurume
  • L'Hospitalet de Llobregat
  • Lecce
  • Lecco
  • Lille
  • Linköping
  • Lombardia
  • Lund
  • Lyon
  • Madrid
  • Mainz
  • Meldola
  • Milano
  • Montpellier
  • Monza
  • Málaga
  • Nagaizumi
  • Nantes
  • Napoli
  • Nice
  • Niigata
  • Oslo
  • Padova
  • Palma
  • Paris
  • Pierre-Bénite
  • Pisa
  • Plérin
  • Ravenna
  • Reggio Emilia
  • Richmond
  • Roma
  • Sabadell
  • Saint-Herblain
  • Santiago de Compostela
  • Sapporo
  • Shreveport
  • Solna
  • Strasbourg
  • Toledo
  • Torino
  • Toulouse
  • Tromsø
  • Udine
  • Uppsala län
  • València
  • Villejuif
  • Wuppertal
  • Zaragoza
  • 横浜市
Trial Identifier:

NCT03556839 2018-000367-83, ENGOT-Cx10, GEICO 68-C, JGOG1084, GOG-3030 ENGOT-Cx10 / BEATcc

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the combination of bevacizumab plus atezolizumab, with no patient selection based on PD-L1 expression, allowing an all-comer assessment of atezolizumab activity. The study is a randomized open label phase III trial to investigate the impact of atezolizumab in combination with bevacizumab and cisplatin or carboplatin /paclitaxel chemotherapy on overall survival and will employ the intent to treat principle, and random assignment to one of the 2 arms will be balanced according to disease histology (squamous cell carcinoma vs adenocarcinoma), prior platinum therapy as a radiation sensitizer (no prior cis-Radiotherapy (RT) versus prior cis-RT) and chemotherapy backbone (cisplatin vs carboplatin). This trial will be run in an open label design due to the following considerations: the control arm is the standard of care for women diagnosed with metastatic, persistant or recurrent cervical cancer because of its impact on overall survival and the primary endpoint of the study is overall survival (OS), so blinding is not needed to ensure a robust assessment.

      Grupo Español de Investigación en Cáncer de Ovario Sponsor
      Phase 3 Phase
      NCT03556839 , ENGOT-Cx10 / BEATcc , 2018-000367-83, ENGOT-Cx10, GEICO 68-C, JGOG1084, GOG-3030 Trial Identifier
      Female Gender
      ≥18 Years Age
      No Healthy Volunteers

      How does the BEATcc clinical trial work?
      This clinical trial is recruiting people who have a type of disease called cervical cancer. In order to take part, patients must have cervical cancer that either has not gone away during previous treatments (known as persistent disease) or have cervical cancer that has previously been treated but has now come back (known as recurrent disease), or newly diagnosed cancer that has already spread to other parts of the body (known as metastatic disease).

      The purpose of this clinical trial is to compare the effects, good or bad, of chemotherapy and bevacizumab when given with or without atezolizumab in patients with cervical cancer. In this clinical trial, you will get chemotherapy and bevacizumab, with or without the new treatment atezolizumab. Chemotherapy plus bevacizumab is the current standard treatment.

      How do I take part in this clinical trial?
      To be able to take part in this clinical trial, you must have been diagnosed with cervical cancer that is persistent, recurrent or metastatic.

      You must not have previously received full doses of chemotherapy or anti-cancer therapy for your cervical cancer since it has come back or spread to other parts of the body, and you must not have previously been treated with bevacizumab. You cannot join the trial if you are pregnant or breastfeeding.

      If you think this clinical trial may be suitable for you and would like to take part, please talk to your doctor. If your doctor thinks that you might be able to take part in this clinical trial, he/she may refer you to the closest clinical trial doctor. They will give you all the information you need to make your decision about taking part in the clinical trial. You can also find the clinical trial locations on this page.

      You will have some further tests to make sure you will be able to take the treatments given in this clinical trial. Some of these tests or procedures may be part of your regular medical care. They may be done even if you do not take part in the clinical trial.

      Before starting the clinical trial, you will be told about any risks and benefits of taking part in the trial. You will also be told what other treatments are available so that you may decide if you still want to take part.

      While taking part in the clinical trial, if you are not currently pregnant but can become pregnant, you will need to either not have heterosexual intercourse or take contraceptive medication for safety reasons.

      What treatment will I be given if I join this clinical trial?
      Everyone who joins this clinical trial will be split into 2 groups randomly (like flipping a coin) and given either:

      • Atezolizumab, chemotherapy and bevacizumab (all given as infusions into your vein every 3 weeks)
      • OR chemotherapy and bevacizumab (all given as infusions into your vein every 3 weeks)

      You will have a 1 in 2 chance of being placed in any group.

      How often will I be seen in follow-up appointments and for how long?
      You will be given the clinical trial treatment for as long as it can help you. You are free to stop this treatment at any time. After being given treatment, you will still be seen by the clinical trial doctor after 1 month and then every 3–4 months. These hospital visits will include checks to see how you are responding to the treatment and any side effects that you may be having. 

       

      What happens if I am unable to take part in this clinical trial?
      If this clinical trial is not suitable for you, you will not be able to take part. Your doctor will suggest other clinical trials that you may be able to take part in or other treatments that you can be given. You will not lose access to any of your regular care.

      For more information about this clinical trial see the For Expert tab on the specific ForPatient page or follow this link to ClinicalTrials.gov: https://clinicaltrials.gov/ct2/show/NCT03556839

      Trial-identifier: NCT03556839

      Trial Summary

      The study will integrate the efficacy of combining the anti programmed death-ligand 1 (anti-PD-L1) agent atezolizumab with the current standard of care in Stage IVB , persistent or recurrent carcinoma of the cervix, namely cisplatin or carboplatin/paclitaxel/bevacizumab. It will be explored the combination of bevacizumab plus atezolizumab, with no patient selection based on PD-L1 expression, allowing an all-comer assessment of atezolizumab activity. The study is a randomized open label phase III trial to investigate the impact of atezolizumab in combination with bevacizumab and cisplatin or carboplatin /paclitaxel chemotherapy on overall survival and will employ the intent to treat principle, and random assignment to one of the 2 arms will be balanced according to disease histology (squamous cell carcinoma vs adenocarcinoma), prior platinum therapy as a radiation sensitizer (no prior cis-Radiotherapy (RT) versus prior cis-RT) and chemotherapy backbone (cisplatin vs carboplatin). This trial will be run in an open label design due to the following considerations: the control arm is the standard of care for women diagnosed with metastatic, persistant or recurrent cervical cancer because of its impact on overall survival and the primary endpoint of the study is overall survival (OS), so blinding is not needed to ensure a robust assessment.

      Grupo Español de Investigación en Cáncer de Ovario Sponsor
      Phase 3 Phase
      NCT03556839 , ENGOT-Cx10 / BEATcc , 2018-000367-83, ENGOT-Cx10, GEICO 68-C, JGOG1084, GOG-3030 Trial Identifier
      Atezolizumab, Bevacizumab, Cisplatin/Carboplatin, Paclitaxel Treatments
      Carcinoma of the Cervix, Stage IVB Condition
      Official Title

      A Randomized Phase III Trial of Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab Versus Platinum Chemotherapy Plus Paclitaxel and Bevacizumab in Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix

      Eligibility Criteria

      Female Gender
      ≥18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      1. Female patients must be ≥18 years of age.
      2. Signed informed consent before any study-specific procedure
      3. Able (in the investigator´s judgment) to comply with the study protocol
      4. GOG/Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
      5. Life expectancy ≥3 months
      6. Histologically- or cytologically-confirmed diagnosis of metastatic (stage IVB), persistent, or recurrent cervical cancer (histologies other than squamous cell, adenocarcinoma, or adenosquamous will be excluded) not amenable for curative treatment with surgery and/or radiation therapy. The inclusion of patients with adenocarcinoma histology will be capped to 20% of the whole study population.
      7. No prior systemic anti-cancer therapy for metastatic or recurrent disease.
      8. Measureable disease by RECIST v1.1 criteria.
      9. A tumor specimen is mandatory at study entry.
      10. Adequate organ function:

        Hemoglobin ≥9 g/dL ANC ≥1.5 × 109/L Lymphocyte count ≥0.5 × 109/L Platelet count ≥100 x 109/L

      11. Adequate liver function:

        Serum albumin ≥2.5 g/dL Total serum bilirubin ≤1.5 ×ULN AST and ALT ≤2.5 × upper limit normal (ULN) or ≤5 × ULN if tumor involvement (liver) is present

      12. Adequate renal function:

        Patients with serum creatinine <1.5 × ULN Urine dipstick for proteinuria <2+.

      13. Adequate coagulation:

        Blood coagulation parameters (PTT, PT/INR): PT such that international normalized ratio (INR) is ≤ 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolus) and a PTT <1.5 × ULN.

      14. Negative Test Results for Hepatitis:

        Negative hepatitis B surface antigen (HBsAg) test at screening Negative total hepatitis B core antibody (HBcAb) test at screening, or positive total HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening.The HBV DNA test will be performed only for patients who have a positive total HBcAb test.

        Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening.The HCV RNA test will be performed only for patients who have a positive HCV antibody test.

      15. Toxicities related to previous treatments must be recovered to < grade 2 (with the exception of alopecia).
      16. Female participants must be postmenopausal (≥ 12 months of non-therapy-induced amenorrhoea) or surgically sterile (absence of ovaries and/or uterus, or who received therapeutic radiation to the pelvis) or otherwise have a negative serum pregnancy test within 7 days of the first study treatment and agree to abstain from heterosexual intercourse or use single or combined contraceptive methods that result in a failure rate of <1% per year during the whole treatment period of the study and for at least 5 months (if the last study dose contained atezolizumab) or 6 months (if the last study dose contained bevacizumab) after the last dose of study treatment.

        • Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal or postovulation methods) and withdrawal are not acceptable methods of contraception
      Exclusion Criteria
      1. Disease that is suitable for local therapy administered with curative intent
      2. Prior radiotherapy delivered using cobalt (rather than a linear accelerator)
      3. Patients with Stage IVA not amendable to concurrent chemo-radiation as primary treatment will not be eligible.
      4. Ongoing disease involving the bladder or rectum at screening/baseline
      5. Evidence of abdominal free air
      6. Bilateral hydronephrosis, unless it can be alleviated by ureteral stent(s) or percutaneous drainage
      7. Patients previously treated with chemotherapy except when used concurrently with radiation therapy. Patients who have received either concurrent paclitaxel with radiation therapy or carboplatin/paclitaxel as adjuvant therapy are ineligible for the study.
      8. Prior treatment with any anti-VEGF drug, including bevacizumab, CD137 agonists or immune checkpoint blockade therapies, anti-PD1, or anti-PDL1 therapeutic antibodies or anti-CTLA 4.
      9. Patients with a concomitant malignancy other than non-melanoma skin cancer. Patients with a prior invasive malignancy (except non-melanoma skin cancer ) who have had any evidence of disease within the last 5 years or whose prior malignancy treatment contraindicates the current protocol therapy.
      10. Known brain metastases or spinal cord compression. It is mandatory to perform a scan of the brain in cases of suspected brain metastases (CT or MRI) or spinal cord compression (MRI).
      11. History or evidence, following a neurological examination, of central nervous system (CNS) disorders, unless properly treated with standard medical treatment,(e.g. uncontrolled epileptic seizures). History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study.
      12. Patients with serious non-healing wound, ulcer, or bone fracture.
      13. Acute intestinal obstruction or sub-occlusion episode in the last 6 months.
      14. Active GI bleeding or GI ulcer
      15. History of Crohn's disease or inflammatory bowel disease
      16. Prior bowel resection ≤6 weeks preceding first study dose
      17. History of diverticulitis requiring medical intervention
      18. NCI CTCAE (version 5.0) grade ≥2 enteritis
      19. Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to Day 1, Cycle 1.
      20. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to Day 1, Cycle 1.
      21. Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels.
      22. Current or recent (within 10 days before the first dose of study drug) chronic daily treatment with aspirin (>325 mg/day), clopidogrel (>75 mg/day), or current or recent (within 10 days before first dose of bevacizumab) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes.
      23. Patients with pre-existing Grade 2 or greater peripheral neuropathy.
      24. History of any grade ≥3 venous thromboembolic event (VTE)
      25. Patients with clinically significant cardiovascular disease.
      26. Left ventricular ejection fraction defined by MUGA/ECHO below the institutional lower limit of normal.
      27. Uncontrolled tumor-related pain
      28. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters (e.g., PleurX) are allowed.
      29. Uncontrolled hypercalcemia (>1.5 mmol/L ionized calcium or calcium >12 mg/dL or corrected serum calcium > ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab.
      30. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, glomerulonephritis or celiac disease.

        History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan

      31. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
      32. Active tuberculosis
      33. Severe infections within 4 weeks prior to Cycle 1, Day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
      34. Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1
      35. Received therapeutic oral or IV antibiotics within 2 weeks prior to Cycle 1, Day 1
      36. Known human immunodeficiency virus (HIV)
      37. Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1 or anticipation that such a live attenuated vaccine will be required during the study Influenza vaccination should be given during influenza season only
      38. Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications
      39. Treatment with systemic immunostimulatory agents (including but not limited to IFNs, IL-2) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to Cycle 1, Day 1
      40. Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to Cycle 1, Day 1 The use of corticosteroids is allowed as premedication for paclitaxel-based regimen. All patients should be premedicated prior to receiving chemotherapy (including with corticosteroids) according to the prescription information of paclitaxel and cisplatin/carboplatin and the institutional standard of care guidance.
      41. Currently participating or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to the first dose of study treatment.
      42. Prior anti-cancer monoclonal antibody (mAb), prior chemotherapy, targeted small molecule therapy as first line treatment for the treatment of metastatic or recurrent cervical cancer.
      43. Women that are breastfeeding or pregnant
      44. Known hypersensitivity to bevacizumab, atezolizumab or any of theirs excipients (including Cremophor)
      45. Demonstration of any other neurological or metabolic dysfunction, found upon physical examination or laboratory tests involving a reasonable suspicion of the existence of a disease or condition that contraindicates the use of an experimental drug, or that involves an increased risk to the patient of treatment-related complications
      46. No medical or psychiatric illness that may impede the performance of a systemic or surgical treatment.

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now